gynecology-2018-scientifictracks

3 / 25

Page 45
conferenceseries.com
Volume 8 Gynecology & Obstetrics
ISSN: 2161-0932 Gynecology 2018
October 08-10, 2018
October 08-10, 2018 | Zurich, Switzerland
5th International Conference on
Gynecology and Obstetrics
Placental growth factor in first trimester aneuploid pregnancies
Michael J Sinosich
Douglass Hanly Moir Pathology, Australia
Placental growth factor (PlGF) is a member of the VEGF (vascular endothelial growth factor) sub-family-a key molecule
in angiogenesis and vasculogenesis. The main source of PlGF during pregnancy is the placental trophoblast. PlGF was
retrospectively quantified (DELFIA® DXpress; PerkinElmer) in women with known pregnancy outcome. Study group consisted
of: i) normal (n=300), ii) abnormal: trisomy 21=56, trisomy 18=23, trisomy 13=6, triploid=15, monosomy X=7. PlGF MoM
values were calculated by LifeCycle v4 (Perkin Elmer), using lot specific derived polynomial regression curve. Median PlGF
MoM values were depressed in pregnancies carrying a foetus affected with: trisomy 21=0.81 (95%CI=0.72–0.90), trisomy
13=0.87 (95%CI=0.79–0.95), trisomy 18=0.89 (95%CI=0.78–1.00), triploidy=0.68 (95%CI=0.59–0.77) or with non-viable
aneuploidies. However, in viable sex chromosome aneuploidy (Monosomy X), PlGF proved less discriminatory with median
MoM=0.91 (95%CI=0.76–1.06). The above findings support the inclusion of PlGF into first trimester biochemical panel
for screening for fetal aneuploidy. Inclusion of PlGF, in a contingent screening model, could detect up to 98.3% of Down’s
syndrome cases. In addition, PlGF has a role in first trimester for assessment of maternal wellbeing, such as, detection of early
onset pre-eclampsia.
Figure 1A: Regressed median (with 0.5 and 2.5 MoM limits) PlGF levels in normal first trimester pregnancies.
Figure 1B: PlGF MoM values in pregnancies carrying Trisomy 21 foetus.
Figure 1C : PlGF MoM values in first trimester pregnancies carrying a confirmed aneuploid foetus, including, Trisomy 13, Trisomy 18,
Trisomy 21 and Triploid (see Methods above).
Biography
Michael J Sinosich has completed his PhD on Trophoblast Physiology and PAPP-A. His research interests include non-invasive assessment of fetomaternal wellbeing. He
is the Director of Prenatal Testing (DHM Pathology) and serves as Consultant at Pictor Ltd, a developer and manufacturer of multiplexed microELISA assay platform. He
has published and presented numerous papers in reputed journals and holds several patents.
Michael J Sinosich, Gynecol Obstet 2018, Volume 8
DOI: 10.4172/2161-0932-C4-033